Dr. Hsiao is the Chief Executive Officer, President, and Co-Founder of Acepodia. Dr. Hsiao has extensive research experience in immune cell therapies, which led to the discovery of components of ACC (Antibody-Cell Conjugation) technology to the invention of the novel cellular immunotherapy ACE (Antibody-Cell Conjugation Effector cells). Dr. Hsiao earned his BS in chemistry from National Taiwan University and his Ph.D. in chemistry and molecular cell biology from the University of California, Berkeley.